Evidence map›Paper›PMID 34526360›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2021

Immunization with a Plasmid DNA Vaccine Encoding the N-Terminus of Insulin-like Growth Factor Binding Protein-2 in Advanced Ovarian Cancer Leads to High-level Type I Immune Responses.

Denise L Cecil, John B Liao, Yushe Dang, Andrew L Coveler, Angela Kask, Yi Yang, Jennifer S Childs, Doreen M Higgins, Mary L Disis

Open access · bronzeAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Exploring treatment options in cancer: Tumor treatment strategies.Signal transduction and targeted therapy · 2024
    Review
  6. Review
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Denise L Cecil *UW Medicine Cancer Vaccine Institute, University of Washington, Seattle, Washington.
John B Liao *UW Medicine Cancer Vaccine Institute, University of Washington, Seattle, Washington.
Yushe DangUW Medicine Cancer Vaccine Institute, University of Washington, Seattle, Washington.
Andrew L CovelerUW Medicine Cancer Vaccine Institute, University of Washington, Seattle, Washington.ORCID 0000-0003-1710-5637
Angela KaskUW Medicine Cancer Vaccine Institute, University of Washington, Seattle, Washington.
Yi YangUW Medicine Cancer Vaccine Institute, University of Washington, Seattle, Washington.
Jennifer S ChildsUW Medicine Cancer Vaccine Institute, University of Washington, Seattle, Washington.
Doreen M HigginsUW Medicine Cancer Vaccine Institute, University of Washington, Seattle, Washington.
Mary L DisisUW Medicine Cancer Vaccine Institute, University of Washington, Seattle, Washington. ndisis@uw.edu.
University of Washington · US

Funding

Transform Dissemination and Implementation Science in CTSA ProgramsUL1TR002319 · NCATS · UNIVERSITY OF WASHINGTON · PI John K. Amory · 2017 to 2026
$100.0M
Vaccinating against IGFBP-2 to prevent ovarian cancer relapseP50CA083636 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DRESCHER, CHARLES, URBAN, NICOLE DENISE · 1999 to 2015
$35.1M
NCATS NIH HHS UL1 TR002319NCI NIH HHS P50 CA083636
6 · The paper itself

Abstract

purposeCancer vaccines targeting nonmutated proteins elicit limited type I T-cell responses and can generate regulatory and type II T cells. Class II epitopes that selectively elicit type I or type II cytokines can be identified in nonmutated cancer-associated proteins. In mice, a T-helper I (Th1) selective insulin-like growth factor binding protein-2 (IGFBP-2) N-terminus vaccine generated high levels of IFNγ secreting T cells, no regulatory T cells, and significant antitumor activity. We conducted a phase I trial of T-helper 1 selective IGFBP-2 vaccination in patients with advanced ovarian cancer. PATIENTS AND

methodsTwenty-five patients were enrolled. The IGFBP-2 N-terminus plasmid-based vaccine was administered monthly for 3 months. Toxicity was graded by NCI criteria and antigen-specific T cells measured by IFNγ/IL10 ELISPOT. T-cell diversity and phenotype were assessed.

resultsThe vaccine was well tolerated, with 99% of adverse events graded 1 or 2, and generated high levels of IGFBP-2 IFNγ secreting T cells in 50% of patients. Both Tbet

conclusionsIGFBP-2 N-terminus Th1 selective vaccination safely induces type I T cells without evidence of regulatory responses.

Indexed as

Cancer VaccinesOvarian NeoplasmsVaccines, DNACD4-Positive T-LymphocytesCD8-Positive T-LymphocytesFemaleHumansImmunizationInsulin-Like Growth Factor Binding Protein 2Lymphocyte ActivationPlasmidsVaccinationCancer VaccinesInsulin-Like Growth Factor Binding Protein 2Vaccines, DNA

Identifiers

PMID34526360
PMCPMC8639726
OpenAlexW3199040526

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.